All In Biotech

Free tool

FAERS Monitor: Xaciato

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215650 or its brand name (Xaciato, Clindamycin Phosphate). Reports on generic versions are filed under their own applications.

Reports

3,566

Serious

2,260

63% of reports

Hospitalization

1,051

Death reported

264

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective375
  • rash257
  • drug hypersensitivity230
  • off label use227
  • diarrhoea190
  • nausea186
  • fatigue169
  • pruritus168
  • pain161
  • condition aggravated135
  • dyspnoea114
  • headache113
  • product use in unapproved indication109
  • pyrexia108
  • erythema101

Reports by year received

View as table
YearReports
200418
200548
200656
200714
200820
200943
201082
201165
201295
2013101
2014102
2015124
2016242
2017182
2018237
2019276
2020210
2021194
2022288
2023305
2024286
2025309
2026268

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,593 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug hypersensitivitySignal2307.06.21,190
rashSignal2573.53.1461
erythemaSignal1012.92.4125
condition aggravatedSignal1352.62.2135
product use in unapproved indicationSignal1092.62.2106
pruritusSignal1682.62.2164
pyrexia1081.81.541
diarrhoea1901.71.560
drug ineffective3751.71.5109
pain1611.51.331
off label use2271.51.343
nausea1861.41.220
fatigue1691.31.110
dyspnoea1141.21.03
headache1131.10.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.